세계의 핵산 의약품 시장(-2031년)

The global Nucleic Acid Drugs market is projected to grow from US$ 14636 million in 2024 to US$ 21722 million by 2031, at a Compound Annual Growth Rate (CAGR) of 7.43% during the forecast period.

The North America market for Nucleic Acid Drugs is estimated to increase from $ 8327.53 million in 2024 to reach $ 11827 million by 2031, at a CAGR of 6.4% during the forecast period of 2025 through 2031.

The China market for Nucleic Acid Drugs is estimated to increase from $ 81.1 million in 2024 to reach $ 1231.84 million by 2031, at a CAGR of 44.83% during the forecast period of 2025 through 2031.

The Europe market for Nucleic Acid Drugs is estimated to increase from $ 3316.94 million in 2024 to reach $ 6063.24 million by 2031, at a CAGR of 10.64% during the forecast period of 2025 through 2031.

The global key companies of Nucleic Acid Drugs include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc. In 2024, the global top five players had a share approximately 86.47% in terms of revenue.

Report Includes

This report presents an overview of global market for Nucleic Acid Drugs market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Nucleic Acid Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Nucleic Acid Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nucleic Acid Drugs revenue, market share and industry ranking of main companies, data from 2020 to 2024. Identification of the major stakeholders in the global Nucleic Acid Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Nucleic Acid Drugs revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc.

Market Segmentation

By Company

On Market Company

• Sarepta Therapeutics
• Ionis Pharmaceuticals
• Alnylam
• Biogen
• Nippon Shinyaku
• Sobi
• Novartis
• BioNTech
• Pfizer
• Moderna Therapeutics
• Jazz Pharmaceuticals
• Novo Nordisk
• AstraZeneca
• Astellas Pharma

On Pipeline Company

• CureVac
• Regulus Therapeutics
• ProQR
• Secarna
• MiNA Therapeutics
• Sylentis
• Arrowhead
• Silence Therapeutics

Segment by Type

• Antisense Oligonucleotides (ASO)
• siRNA
• mRNA

Segment by Application

• Neuromuscular Diseases
• hATTR
• COVID-19
• Other

By Region

• North America
• United States
• Canada
• China
• Asia-Pacific
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Rest of Europe
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Middle East
• Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Nucleic Acid Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nucleic Acid Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acid Drugs revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Nucleic Acid Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
  • 1.2.2 Antisense Oligonucleotides (ASO)
  • 1.2.3 siRNA
  • 1.2.4 mRNA
• 1.3 Market by Application
  • 1.3.1 Global Nucleic Acid Drugs Market Share by Application: 2020 VS 2024 VS 2031
  • 1.3.2 Neuromuscular Diseases
  • 1.3.3 hATTR
  • 1.3.4 COVID-19
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Nucleic Acid Drugs Market Perspective (2020-2031)
• 2.2 Global Nucleic Acid Drugs Growth Trends by Region
  • 2.2.1 Global Nucleic Acid Drugs Market Size by Region: 2020 VS 2024 VS 2031
  • 2.2.2 Nucleic Acid Drugs Market Size by Region (2020-2031)
• 2.3 Nucleic Acid Drugs Market Dynamics
  • 2.3.1 Nucleic Acid Drugs Industry Trends
  • 2.3.2 Nucleic Acid Drugs Market Drivers
  • 2.3.3 Nucleic Acid Drugs Market Challenges
  • 2.3.4 Nucleic Acid Drugs Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Revenue Nucleic Acid Drugs by Players
  • 3.1.1 Global Nucleic Acid Drugs Revenue by Players (2020-2025)
  • 3.1.2 Global Nucleic Acid Drugs Revenue Market Share by Players (2020-2025)
• 3.2 Global Nucleic Acid Drugs Market by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Global Key Players of Nucleic Acid Drugs, Ranking by Revenue, 2023 VS 2024 VS 2025
• 3.4 Global Market Concentration Ratio
  • 3.4.1 Global Nucleic Acid Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Drugs Revenue in 2024
• 3.5 Global Key Players of Nucleic Acid Drugs Head office and Area Served
• 3.6 Global Key Players of Nucleic Acid Drugs, Product and Application
• 3.7 Global Key Players of Nucleic Acid Drugs, Date of Enter into This Industry
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type

• 4.1 Global Nucleic Acid Drugs Historic Market Size by Type (2020-2025)
• 4.2 Global Nucleic Acid Drugs Forecasted Market Size by Type (2026-2031)

5 Breakdown Data by Application

• 5.1 Global Nucleic Acid Drugs Historic Market Size by Application (2020-2025)
• 5.2 Global Nucleic Acid Drugs Forecasted Market Size by Application (2026-2031)

6 North America

• 6.1 North America Nucleic Acid Drugs Market Size (2020-2031)
• 6.2 North America Market Size by Type
  • 6.2.1 North America Nucleic Acid Drugs Market Size by Type (2020-2031)
  • 6.2.2 North America Nucleic Acid Drugs Market Share by Type (2020-2031)
• 6.3 North America Market Size by Application
  • 6.3.1 North America Nucleic Acid Drugs Market Size by Application (2020-2031)
  • 6.3.2 North America Nucleic Acid Drugs Market Share by Application (2020-2031)
• 6.4 North America Market Size by Country
  • 6.4.1 North America Nucleic Acid Drugs Market Size by Country: 2020 VS 2024 VS 2031
  • 6.4.2 North America Nucleic Acid Drugs Market Size by Country (2020-2031)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Nucleic Acid Drugs Market Size (2020-2031)
• 7.2 Europe Market Size by Type
  • 7.2.1 Europe Nucleic Acid Drugs Market Size by Type (2020-2031)
  • 7.2.2 Europe Nucleic Acid Drugs Market Share by Type (2020-2031)
• 7.3 Europe Market Size by Application
  • 7.3.1 Europe Nucleic Acid Drugs Market Size by Application (2020-2031)
  • 7.3.2 Europe Nucleic Acid Drugs Market Share by Application (2020-2031)
• 7.4 Europe Market Size by Country
  • 7.4.1 Europe Nucleic Acid Drugs Market Size by Country: 2020 VS 2024 VS 2031
  • 7.4.2 Europe Nucleic Acid Drugs Market Size by Country (2020-2025)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia

8 China

• 8.1 China Nucleic Acid Drugs Market Size (2020-2031)
• 8.2 China Market Size by Type
  • 8.2.1 China Nucleic Acid Drugs Market Size by Type (2020-2031)
  • 8.2.2 China Nucleic Acid Drugs Market Share by Type (2020-2031)
• 8.3 China Market Size by Application
  • 8.3.1 China Nucleic Acid Drugs Market Size by Application (2020-2031)
  • 8.3.2 China Nucleic Acid Drugs Market Share by Application (2020-2031)

9 Asia (excluding China)

• 9.1 Asia Nucleic Acid Drugs Market Size (2020-2031)
• 9.2 Asia Market Size by Type
  • 9.2.1 Asia Nucleic Acid Drugs Market Size by Type (2020-2031)
  • 9.2.2 Asia Nucleic Acid Drugs Market Share by Type (2020-2031)
• 9.3 Asia Market Size by Application
  • 9.3.1 Asia Nucleic Acid Drugs Market Size by Application (2020-2031)
  • 9.3.2 Asia Nucleic Acid Drugs Market Share by Application (2020-2031)
• 9.4 Asia Market Size by Region
  • 9.4.1 Asia Nucleic Acid Drugs Market Size by Region: 2020 VS 2024 VS 2031
  • 9.4.2 Asia Nucleic Acid Drugs Market Size by Region (2020-2031)
  • 9.4.3 Japan
  • 9.4.4 South Korea
  • 9.4.5 Southeast Asia
  • 9.4.6 India
  • 9.4.7 Australia

10 Middle East, Africa, and Latin America

• 10.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size (2020-2031)
• 10.2 Middle East, Africa, and Latin America Market Size by Type
  • 10.2.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Type (2020-2031)
  • 10.2.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Share by Type (2020-2031)
• 10.3 Middle East, Africa, and Latin America Market Size by Application
  • 10.3.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Application (2020-2031)
  • 10.3.2 Middle East, Africa, and Latin America Market Share by Application (2020-2031)
• 10.4 Middle East, Africa, and Latin America Market Size by Country
  • 10.4.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country: 2020 VS 2024 VS 2031
  • 10.4.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country (2020-2031)
  • 10.4.3 Brazil
  • 10.4.4 Mexico
  • 10.4.5 Middle East
  • 10.4.6 Africa

11 Key Players Profiles

• 11.1 Sarepta Therapeutics
  • 11.1.1 Sarepta Therapeutics Company Details
  • 11.1.2 Sarepta Therapeutics Business Overview
  • 11.1.3 Sarepta Therapeutics Nucleic Acid Drugs Introduction
  • 11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.1.5 Sarepta Therapeutics Recent Development
• 11.2 Ionis Pharmaceuticals
  • 11.2.1 Ionis Pharmaceuticals Company Details
  • 11.2.2 Ionis Pharmaceuticals Business Overview
  • 11.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Introduction
  • 11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.2.5 Ionis Pharmaceuticals Recent Development
• 11.3 Alnylam
  • 11.3.1 Alnylam Company Details
  • 11.3.2 Alnylam Business Overview
  • 11.3.3 Alnylam Nucleic Acid Drugs Introduction
  • 11.3.4 Alnylam Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.3.5 Alnylam Recent Development
• 11.4 Biogen
  • 11.4.1 Biogen Company Details
  • 11.4.2 Biogen Business Overview
  • 11.4.3 Biogen Nucleic Acid Drugs Introduction
  • 11.4.4 Biogen Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.4.5 Biogen Recent Development
• 11.5 Nippon Shinyaku
  • 11.5.1 Nippon Shinyaku Company Details
  • 11.5.2 Nippon Shinyaku Business Overview
  • 11.5.3 Nippon Shinyaku Nucleic Acid Drugs Introduction
  • 11.5.4 Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.5.5 Nippon Shinyaku Recent Development
• 11.6 Sobi
  • 11.6.1 Sobi Company Details
  • 11.6.2 Sobi Business Overview
  • 11.6.3 Sobi Nucleic Acid Drugs Introduction
  • 11.6.4 Sobi Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.6.5 Sobi Recent Development
• 11.7 Novartis
  • 11.7.1 Novartis Company Details
  • 11.7.2 Novartis Business Overview
  • 11.7.3 Novartis Nucleic Acid Drugs Introduction
  • 11.7.4 Novartis Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.7.5 Novartis Recent Development
• 11.8 BioNTech
  • 11.8.1 BioNTech Company Details
  • 11.8.2 BioNTech Business Overview
  • 11.8.3 BioNTech Nucleic Acid Drugs Introduction
  • 11.8.4 BioNTech Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.8.5 BioNTech Recent Development
• 11.9 Pfizer
  • 11.9.1 Pfizer Company Details
  • 11.9.2 Pfizer Business Overview
  • 11.9.3 Pfizer Nucleic Acid Drugs Introduction
  • 11.9.4 Pfizer Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.9.5 Pfizer Recent Development
• 11.10 Moderna Therapeutics
  • 11.10.1 Moderna Therapeutics Company Details
  • 11.10.2 Moderna Therapeutics Business Overview
  • 11.10.3 Moderna Therapeutics Nucleic Acid Drugs Introduction
  • 11.10.4 Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.10.5 Moderna Therapeutics Recent Development
• 11.11 Jazz Pharmaceuticals
  • 11.11.1 Jazz Pharmaceuticals Company Details
  • 11.11.2 Jazz Pharmaceuticals Business Overview
  • 11.11.3 Jazz Pharmaceuticals Nucleic Acid Drugs Introduction
  • 11.11.4 Jazz Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.11.5 Jazz Pharmaceuticals Recent Development
• 11.12 Novo Nordisk
  • 11.12.1 Novo Nordisk Company Details
  • 11.12.2 Novo Nordisk Business Overview
  • 11.12.3 Novo Nordisk Nucleic Acid Drugs Introduction
  • 11.12.4 Novo Nordisk Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.12.5 Novo Nordisk Recent Development
• 11.13 AstraZeneca
  • 11.13.1 AstraZeneca Company Details
  • 11.13.2 AstraZeneca Business Overview
  • 11.13.3 AstraZeneca Nucleic Acid Drugs Introduction
  • 11.13.4 AstraZeneca Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.13.5 AstraZeneca Recent Development
• 11.14 Astellas Pharma
  • 11.14.1 Astellas Pharma Company Details
  • 11.14.2 Astellas Pharma Business Overview
  • 11.14.3 Astellas Pharma Nucleic Acid Drugs Introduction
  • 11.14.4 Astellas Pharma Revenue in Nucleic Acid Drugs Business (2020-2025)
  • 11.14.5 Astellas Pharma Recent Development
• 11.15 CureVac
  • 11.15.1 CureVac Company Details
  • 11.15.2 CureVac Business Overview
  • 11.15.3 CureVac Nucleic Acid Drugs Introduction
  • 11.15.4 CureVac Recent Development
• 11.16 Regulus Therapeutics
  • 11.16.1 Regulus Therapeutics Company Details
  • 11.16.2 Regulus Therapeutics Business Overview
  • 11.16.3 Regulus Therapeutics Nucleic Acid Drugs Introduction
  • 11.16.4 Regulus Therapeutics Recent Development
• 11.17 ProQR
  • 11.17.1 ProQR Company Details
  • 11.17.2 ProQR Business Overview
  • 11.17.3 ProQR Nucleic Acid Drugs Introduction
  • 11.17.4 ProQR Recent Development
• 11.18 Secarna
  • 11.18.1 Secarna Company Details
  • 11.18.2 Secarna Business Overview
  • 11.18.3 Secarna Nucleic Acid Drugs Introduction
  • 11.18.4 Secarna Recent Development
• 11.19 MiNA Therapeutics
  • 11.19.1 MiNA Therapeutics Company Details
  • 11.19.2 MiNA Therapeutics Business Overview
  • 11.19.3 MiNA Therapeutics Nucleic Acid Drugs Introduction
  • 11.19.4 MiNA Therapeutics Recent Development
• 11.20 Sylentis
  • 11.20.1 Sylentis Company Details
  • 11.20.2 Sylentis Business Overview
  • 11.20.3 Sylentis Nucleic Acid Drugs Introduction
  • 11.20.4 Sylentis Recent Development
• 11.21 Arrowhead
  • 11.21.1 Arrowhead Company Details
  • 11.21.2 Arrowhead Business Overview
  • 11.21.3 Arrowhead Nucleic Acid Drugs Introduction
  • 11.21.4 Arrowhead Recent Development
• 11.22 Silence Therapeutics
  • 11.22.1 Silence Therapeutics Company Details
  • 11.22.2 Silence Therapeutics Business Overview
  • 11.22.3 Silence Therapeutics Nucleic Acid Drugs Introduction
  • 11.22.4 Silence Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Author Details
• 13.3 Disclaimer 141